"Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study - The TRIBUNE study".
暂无分享,去创建一个
K. Bartziokas | P. Katerelos | P. Bakakos | Konstantinos Porpodis | Aliki Korkontzelou | Panagiotis Chatziapostolou | P. Efstathopoulos
[1] W. Pohl,et al. TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD. , 2021, Respiratory medicine.
[2] Kevin McCarthy,et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.
[3] N. Papadopoulos,et al. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group , 2019, European Respiratory Journal.
[4] R. Stanford,et al. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population , 2019, International journal of chronic obstructive pulmonary disease.
[5] Kelly H Zou,et al. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making , 2018, Journal of multidisciplinary healthcare.
[6] N. Roche,et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial , 2018, The Lancet.
[7] Mario Cazzola,et al. Adherence to COPD treatment: Myth and reality. , 2017, Respiratory medicine.
[8] Dave Singh,et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial , 2017, The Lancet.
[9] Dave Singh,et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial , 2016, The Lancet.
[10] P. Jones,et al. The COPD Assessment Test: What Do We Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients Into GOLD Stages. , 2016, Chest.
[11] D. Price,et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK , 2015, International journal of chronic obstructive pulmonary disease.
[12] B. Cosío,et al. Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for Asthma and COPD Patients , 2016, Journal of aerosol medicine and pulmonary drug delivery.
[13] S. Kon,et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.
[14] D. Elbourne,et al. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects☆ , 2014, Journal of clinical epidemiology.
[15] P. Jones,et al. Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.
[16] J. Bourbeau,et al. Patient adherence in COPD , 2008, Thorax.
[17] M. Pistolesi,et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.
[18] D. Mannino,et al. Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.
[19] S. Spencer,et al. Impact of preventing exacerbations on deterioration of health status in COPD , 2004, European Respiratory Journal.